Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Barhemsys Generic Name & Formulations
Legal Class
Rx
General Description
Amisulpride 2.5mg/mL; soln for IV infusion.
Pharmacological Class
Dopamine-2 receptor antagonist.
How Supplied
Single-dose vial (2mL)—10
Manufacturer
Generic Availability
NO
Barhemsys Indications
Indications
Prevention of postoperative nausea and vomiting (PONV), either alone or in combination with an antiemetic of a different class. Treatment of PONV in patients who have received antiemetic prophylaxis with an agent of a different class or have not received prophylaxis.
Barhemsys Dosage and Administration
Adult
Prevention: 5mg as a single IV inj infused over 1–2mins at the time of induction of anesthesia. Treatment: 10mg as a single IV inj infused over 1–2mins in the event of nausea and/or vomiting after a surgical procedure.
Children
Not established.
Barhemsys Contraindications
Not Applicable
Barhemsys Boxed Warnings
Not Applicable
Barhemsys Warnings/Precautions
Warnings/Precautions
Risk of QT prolongation. Avoid in congenital long QT syndrome. Monitor ECG in those with preexisting arrhythmias/cardiac conduction disorders, electrolyte abnormalities (eg, hypokalemia, hypomagnesemia), CHF, or other medical conditions known to prolong the QT interval. Severe renal impairment (eGFR <30mL/min/1.73m2): avoid. Pregnancy. Nursing mothers: consider interrupting breastfeeding or pumping/discarding breast milk for 48hrs after dose.
Barhemsys Pharmacokinetics
See Literature
Barhemsys Interactions
Interactions
Avoid concomitant droperidol, levodopa. Concomitant other drugs known to prolong the QT interval (eg, ondansetron): monitor ECG.
Barhemsys Adverse Reactions
Adverse Reactions
Increased blood prolactin concentrations, chills, hypokalemia, procedural hypotension, abdominal distension, infusion site pain.
Barhemsys Clinical Trials
See Literature
Barhemsys Note
Not Applicable
Barhemsys Patient Counseling
See Literature
Images
